Importance of surrogate markers in evaluation of antiviral therapy for HIV infection

被引：13

作者：

Deyton, L

机构：

[1] Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1996年 / 276卷 / 02期

关键词：

D O I：

10.1001/jama.276.2.159

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：159 / 160

页数：2

共 28 条

[1] CD4+ LYMPHOCYTES ARE AN INCOMPLETE SURROGATE MARKER FOR CLINICAL PROGRESSION IN PERSONS WITH ASYMPTOMATIC HIV-INFECTION TAKING ZIDOVUDINE [J].

CHOI, SS ;

LAGAKOS, SW ;

SCHOOLEY, RT ;

VOLBERDING, PA .

ANNALS OF INTERNAL MEDICINE, 1993, 118 (09) :674-680

[2] Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine [J].

Collier, AC ;

Coombs, RW ;

Schoenfeld, DA ;

Bassett, RL ;

Timpone, J ;

Baruch, A ;

Jones, M ;

Facey, K ;

Whitacre, C ;

McAuliffe, VJ ;

Friedman, HM ;

Merigan, TC ;

Reichman, RC ;

Hooper, C ;

Corey, L .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (16) :1011-1017

[3] PLASMA VIREMIA IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTION [J].

COOMBS, RW ;

COLLIER, AC ;

ALLAIN, JP ;

NIKORA, B ;

LEUTHER, M ;

GJERSET, GF ;

COREY, L .

NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (24) :1626-1631

[4]

DAQUILA RT, 1995, P 2 NAT C HUM RETR R

[5] SERUM P24 ANTIGEN LEVEL AS AN INTERMEDIATE END-POINT IN CLINICAL-TRIALS OF ZIDOVUDINE IN PEOPLE INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].

DEGRUTTOLA, V ;

BECKETT, LA ;

COOMBS, RW ;

ARDUINO, JM ;

BALFOUR, HH ;

RASHEED, S ;

HOLLINGER, FB ;

FISCHL, MA ;

VOLBERDING, P ;

GROUP, TACT .

JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (04) :713-721

[6] RISK OF AIDS RELATED COMPLEX AND AIDS IN HOMOSEXUAL MEN WITH PERSISTENT HIV ANTIGENEMIA [J].

DEWOLF, F ;

GOUDSMIT, J ;

PAUL, DA ;

LANGE, JMA ;

HOOIJKAAS, C ;

SCHELLEKENS, P ;

COUTINHO, RA ;

VANDERNOORDAA, J .

BMJ-BRITISH MEDICAL JOURNAL, 1987, 295 (6598) :569-572

[7] TREATMENT WITH LAMIVUDINE, ZIDOVUDINE, OR BOTH IN HIV-POSITIVE PATIENTS WITH 200 TO 500 CD4+ CELLS PER CUBIC MILLIMETER [J].

ERON, JJ ;

BENOIT, SL ;

JEMSEK, J ;

MACARTHUR, RD ;

SANTANA, J ;

QUINN, JB ;

KURITZKES, DR ;

FALLON, MA ;

RUBIN, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1662-1669

[8] PREDICTIVE MARKERS FOR THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) IN HEMOPHILIACS - PERSISTENCE OF P24 ANTIGEN AND LOW T4 CELL COUNT [J].

EYSTER, ME ;

BALLARD, JO ;

GAIL, MH ;

DRUMMOND, JE ;

GOEDERT, JJ .

ANNALS OF INTERNAL MEDICINE, 1989, 110 (12) :963-969

[9] THE HUMAN IMMUNODEFICIENCY VIRUS - INFECTIVITY AND MECHANISMS OF PATHOGENESIS [J].

FAUCI, AS .

SCIENCE, 1988, 239 (4840) :617-622

[10] SURROGATE AND AUXILIARY END-POINTS IN CLINICAL-TRIALS, WITH POTENTIAL APPLICATIONS IN CANCER AND AIDS RESEARCH [J].

FLEMING, TR ;

PRENTICE, RL ;

PEPE, MS ;

GLIDDEN, D .

STATISTICS IN MEDICINE, 1994, 13 (09) :955-968

← 1 2 3 →